Navigation Links
Stereotaxis Appoints Senior Vice President, North America
Date:6/20/2008

Responsible for Sales and Clinical Services

ST. LOUIS, June 20 /PRNewswire-FirstCall/ -- Stereotaxis, Inc. (Nasdaq: STXS) announced today that it has enhanced its senior management team for North American sales and clinical services with the appointment of Louis Ruggiero as Senior Vice President, North America. Mr. Ruggiero was most recently Chief Sales & Marketing Officer at DJ Orthopedics, formerly was President and CEO of Titan Scan Technologies Corporation, and is a 10-year veteran at General Electric Medical Systems. Mr. Ruggiero will report to Michael P. Kaminski, President and Chief Operating Officer of Stereotaxis.

"Lou brings to Stereotaxis 25 years of progressive sales, marketing and general management experience in the healthcare industry," said Bevil J. Hogg, Chief Executive Officer of Stereotaxis. "His background includes sales leadership positions at both emerging and well-established medical device companies. We anticipate that Lou will play a key role, strengthening our sales effort and driving operational efficiencies. He has a track record for generating strong revenue growth and driving profits, and we believe that Lou will quickly become an important asset to our company."

Mr. Ruggiero, 48, joins Stereotaxis from DJ Orthopedics (DJO), where he served as Chief Sales and Marketing Officer and Corporate Officer from 2003 until the Company was acquired by The Blackstone Group in 2007. During his four-year tenure at DJO, Mr. Ruggiero helped the Company double sales growth to $375 million. Prior to joining DJO, Mr. Ruggiero spent four years at Titan Scan Technologies Corporation as President and Chief Executive Officer. In that time he led Titan to more than $50 million in sales, from $7 million.

Mr. Ruggiero earned his M.B.A. in General Management and Marketing at the J.L. Kellogg Graduate School of Management at Northwestern University, and his B.A. in Political Science and Interpersonal Communication at
'/>"/>

SOURCE Stereotaxis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Stereotaxis Niobe System Used to Perform More Than 10,000 Procedures Worldwide
2. Stereotaxis Announces FDA Approval of Its Partnered Magnetic Irrigated Catheter
3. Stereotaxis Appoints David Burkhardt, M.D. as Chief Medical Officer
4. Stereotaxis Reports Fourth Quarter and Full Year 2007 Financial Results
5. Stereotaxis Highlights a Transatlantic Arrhythmia Procedure Collaboration With the Odyssey(TM) Network
6. Stereotaxis Market Leadership Highlighted at Heart Rhythm 2008
7. Stereotaxis to Present at the Seventh Annual JMP Securities Research Conference
8. BioVex Appoints Dr. Thaddeus Pullano as VP, Quality Assurance
9. Codexis Appoints Singapore Laboratories Managing Director
10. Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel
11. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... July 28, 2014 Research and Markets ... Synthetic Biology Market 2014-2018" report to their offering. ... The term synthetic biology covers the designing and engineering ... well as the redesigning of natural biological systems that ... be a form of extreme genetic engineering because it ...
(Date:7/28/2014)... PA & Boston, MA (PRWEB) July 28, 2014 ... collaboration agreements with two researchers to further develop potential ... deadly malignant brain tumor, in combination with their patented ... by ITI and Duke University, are based on the ... Chief, Division of Neurosurgery at The Preston Robert Tisch ...
(Date:7/28/2014)... 2014 The global market for biotechnology ... according to a new study by Grand View Research, ... for effective vaccines and drugs in an attempt to ... is expected to drive market demand over the next ... productivity via the use of genetically engineered seeds is ...
(Date:7/28/2014)... July 28, 2014 The National Model ... Muncie IN, is pleased to announce that it has ... Museum of the United States Air Force. , The ... process that concluded this spring with an on-site inspection ... OH museum. , The National Museum of the ...
Breaking Biology Technology:Global Synthetic Biology Market 2014-2018 2String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 2String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 3String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 4Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 2Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 3Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 4AMA’s National Model Aviation Museum Granted Full Civilian Museum Certification by the National Museum of the United States Air Force 2
... epigenetic anticancer program at Pharmion ... inhibitors - ... Significant opportunity to explore combination epigenetic therapies, BOULDER, Colo. ... and MethylGene Inc. (TSX: MYG) today announced a,research collaboration for ...
... /Xinhua-PRNewswire-FirstCall/ --,Kiwa Bio-Tech Products Group Corporation (OTC Bulletin Board: ... increased more than,35% over the first quarter of 2007 ... for the same period in the previous year. ... compared to only,$24,374 in the first half of 2006. ...
... COLUMBIA, Md., Aug. 14 Martek Biosciences,Corporation announced that ... of fiscal 2007 on September 5, 2007, at approximately ... 4:45 p.m. EDT Martek,will hold a conference call to ... with investors. The call is expected to be approximately ...
Cached Biology Technology:Pharmion and MethylGene Announce Collaboration to Develop Sirtuin Inhibitors as Anti-Cancer Agents 2Pharmion and MethylGene Announce Collaboration to Develop Sirtuin Inhibitors as Anti-Cancer Agents 3Pharmion and MethylGene Announce Collaboration to Develop Sirtuin Inhibitors as Anti-Cancer Agents 4Pharmion and MethylGene Announce Collaboration to Develop Sirtuin Inhibitors as Anti-Cancer Agents 5Pharmion and MethylGene Announce Collaboration to Develop Sirtuin Inhibitors as Anti-Cancer Agents 6Kiwa Bio-Tech Revenues for 1st Half Exceed $3.25 Million 2Kiwa Bio-Tech Revenues for 1st Half Exceed $3.25 Million 3Kiwa Bio-Tech Revenues for 1st Half Exceed $3.25 Million 4Kiwa Bio-Tech Revenues for 1st Half Exceed $3.25 Million 5Kiwa Bio-Tech Revenues for 1st Half Exceed $3.25 Million 6Martek to Announce Third Quarter 2007 Results on September 5, 2007 2
(Date:7/28/2014)... Wyss Institute for Biologically Inspired Engineering at Harvard ... will be commercialized by a newly formed private ... and personalized medicine products. The announcement ... of Technology Development (OTD) and the start-up Emulate ... automated human Organs-on-Chips platform. , "This is ...
(Date:7/27/2014)... that nicotine and cotinine, a metabolite of nicotine, can ... in smoke. , The carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone or NNK is ... ends up in the tobacco smoke. Once inhaled, it ... is activated by a variety of enzymes called Cytochrome ... nicotine can partially interfere with the activation of NNK, ...
(Date:7/27/2014)... of mayfly in the southern Western Ghats, a mountain range ... the first time that any mayfly belonging to the genus ... The new species, called Labiobaetis soldani , "is named ... to the understanding of the Ephemeroptera of Palaearctic and Oriental ... the new mayfly in the Journal of Insect Science ...
Breaking Biology News(10 mins):Wyss Institute's technology translation engine launches 'Organs-on-Chips' company 2Wyss Institute's technology translation engine launches 'Organs-on-Chips' company 3Nicotine found to inhibit DNA-strand break caused by a certain carcinogen in smoke 2
... The discovery by Uppsala University researchers of a previously ... ways brings new potential for early diagnosis of a ... the Web edition of the American journal Proceedings ... provide new knowledge of the cause of common diseases ...
... native fishes in the Pacific Northwest are threatened or ... are expended annually on researching their populations and on ... been directed toward to the impacts of habitat alteration, ... published in the March 2009 issue of BioScience ...
... Society for Clinical and Economic Aspects of Osteoporosis and ... scientific programme for the upcoming IOF WCO- ECCEO10, a ... May 5-8, 2010. Complete programme information, online ... www.iofwco-ecceo10.org . IOF WCO-ECCEO10 will offer ...
Cached Biology News:World Congress on Osteoporosis 2010 presents outstanding scientific program 2
...
Mouse polyclonal antibody to QPRT - quinolinate phosphoribosyltransferase (nicotinate-nucleotide pyrophosphorylase (carboxylating))...
... Protein Extraction Reagent is a ... that means no scraping, no ... With M-PER Reagent, rapid lysis ... at room temperature, yielding 25% ...
... FailSafe™ PCR System is the only PCR ... time and every time. It provides accuracy, ... the source or the property of the ... PCR Enzyme Mix, a unique blend of ...
Biology Products: